Kintegral Advisory LLC Sells 2,211 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Kintegral Advisory LLC reduced its position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 32.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 4,511 shares of the company's stock after selling 2,211 shares during the period. Kintegral Advisory LLC's holdings in HCA Healthcare were worth $1,559,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Atwood & Palmer Inc. acquired a new stake in shares of HCA Healthcare during the 1st quarter worth about $28,000. Bartlett & CO. Wealth Management LLC grew its position in shares of HCA Healthcare by 888.9% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 89 shares of the company's stock valued at $31,000 after purchasing an additional 80 shares during the last quarter. ORG Partners LLC boosted its stake in HCA Healthcare by 344.0% in the 1st quarter. ORG Partners LLC now owns 111 shares of the company's stock valued at $38,000 after purchasing an additional 86 shares during the period. Tidemark LLC bought a new position in shares of HCA Healthcare during the fourth quarter worth approximately $36,000. Finally, Legacy Investment Solutions LLC raised its holdings in HCA Healthcare by 99.0% in the 4th quarter. Legacy Investment Solutions LLC now owns 191 shares of the company's stock valued at $62,000 after acquiring an additional 95 shares in the last quarter. 62.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Jon M. Foster sold 15,698 shares of the company's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $369.32, for a total transaction of $5,797,585.36. Following the transaction, the chief operating officer owned 12,646 shares of the company's stock, valued at $4,670,420.72. This represents a 55.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.30% of the company's stock.

HCA Healthcare Stock Down 1.4%

HCA traded down $5.20 during mid-day trading on Friday, reaching $372.84. 943,125 shares of the stock were exchanged, compared to its average volume of 1,461,363. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $417.14. The stock has a market capitalization of $89.69 billion, a PE ratio of 16.58, a price-to-earnings-growth ratio of 1.30 and a beta of 1.47. The company has a 50 day moving average price of $370.64 and a two-hundred day moving average price of $338.65. The company has a debt-to-equity ratio of 69.07, a quick ratio of 1.06 and a current ratio of 1.19.

HCA Healthcare (NYSE:HCA - Get Free Report) last released its earnings results on Friday, April 25th. The company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.75 by $0.70. The company had revenue of $18.32 billion during the quarter, compared to analyst estimates of $18.26 billion. HCA Healthcare had a return on equity of 1,063.91% and a net margin of 8.07%. HCA Healthcare's quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $5.36 earnings per share. As a group, research analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 16th were given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date was Monday, June 16th. HCA Healthcare's dividend payout ratio is currently 12.81%.

Analysts Set New Price Targets

Several research analysts have commented on HCA shares. Royal Bank Of Canada reissued an "outperform" rating and set a $404.00 target price (up previously from $376.00) on shares of HCA Healthcare in a research note on Monday, June 23rd. Barclays set a $416.00 price target on HCA Healthcare and gave the company an "overweight" rating in a research note on Monday, June 2nd. Stephens upgraded HCA Healthcare to a "strong-buy" rating in a research report on Monday, June 2nd. Robert W. Baird reaffirmed a "neutral" rating and issued a $336.00 price objective (down previously from $396.00) on shares of HCA Healthcare in a research note on Tuesday, April 15th. Finally, Guggenheim initiated coverage on shares of HCA Healthcare in a research report on Wednesday, April 9th. They set a "neutral" rating on the stock. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, HCA Healthcare presently has a consensus rating of "Moderate Buy" and a consensus target price of $395.71.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.